Stemline Therapeutics’ (STML) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Stemline Therapeutics (NASDAQ:STML) in a research report released on Friday morning. The brokerage currently has a $38.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on STML. Cowen reaffirmed a buy rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. BidaskClub cut Stemline Therapeutics from a buy rating to a hold rating in a report on Thursday, December 7th. ValuEngine raised Stemline Therapeutics from a sell rating to a hold rating in a report on Sunday, December 31st. Finally, Zacks Investment Research raised Stemline Therapeutics from a sell rating to a hold rating in a report on Friday, January 5th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Stemline Therapeutics has an average rating of Buy and an average target price of $33.75.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at $15.85 on Friday. Stemline Therapeutics has a twelve month low of $5.80 and a twelve month high of $17.40.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. equities research analysts anticipate that Stemline Therapeutics will post -2.68 EPS for the current year.

In related news, COO Kenneth Hoberman sold 11,943 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Gionco sold 4,250 shares of the stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. Insiders have sold a total of 42,216 shares of company stock worth $591,925 in the last 90 days. 15.70% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Stemline Therapeutics by 4.7% during the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock valued at $7,946,000 after buying an additional 38,615 shares during the period. Lyon Street Capital LLC raised its holdings in Stemline Therapeutics by 331.1% during the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after buying an additional 415,867 shares during the period. State Street Corp raised its holdings in Stemline Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock valued at $3,179,000 after buying an additional 35,116 shares during the period. Northern Trust Corp raised its holdings in Stemline Therapeutics by 18.0% during the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock valued at $2,529,000 after buying an additional 41,898 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Stemline Therapeutics by 82.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock valued at $2,434,000 after buying an additional 98,775 shares during the period. Institutional investors own 43.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2018/02/05/stemline-therapeutics-stml-buy-rating-reaffirmed-at-hc-wainwright.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit